272 related articles for article (PubMed ID: 19926582)
21. Validation of tissue microarray technology in vulvar cancer.
Fons G; van der Velden J; Burger M; ten Kate F
Int J Gynecol Pathol; 2009 Jan; 28(1):76-82. PubMed ID: 19047904
[TBL] [Abstract][Full Text] [Related]
22. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma.
Drev P; Grazio SF; Bracko M
Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):179-84. PubMed ID: 18227723
[TBL] [Abstract][Full Text] [Related]
23. iCon-TMA for control and quantitation of immunohistochemistry and in situ molecular pathology analysis.
Petersen I; Blind C; Koepenik A; Dietel M; Krenn V
Pathol Res Pract; 2007; 203(8):629-31. PubMed ID: 17590280
[TBL] [Abstract][Full Text] [Related]
24. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial.
Mengel M; von Wasielewski R; Wiese B; Rüdiger T; Müller-Hermelink HK; Kreipe H
J Pathol; 2002 Nov; 198(3):292-9. PubMed ID: 12375261
[TBL] [Abstract][Full Text] [Related]
25. Biotin-free systems provide stronger immunohistochemical signal in oestrogen receptor evaluation of breast cancer.
Rocha RM; Miller K; Soares F; Schenka N; Vassallo J; Gobbi H
J Clin Pathol; 2009 Aug; 62(8):699-704. PubMed ID: 19447833
[TBL] [Abstract][Full Text] [Related]
26. Robust gridding of TMAs after whole-slide imaging using template matching.
Lahrmann B; Halama N; Westphal K; Ernst C; Elsawaf Z; Sinn P; Bosch FX; Dickhaus H; Jäger D; Schirmacher P; Grabe N
Cytometry A; 2010 Dec; 77(12):1169-76. PubMed ID: 20662092
[TBL] [Abstract][Full Text] [Related]
27. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies.
Bubendorf L; Nocito A; Moch H; Sauter G
J Pathol; 2001 Sep; 195(1):72-9. PubMed ID: 11568893
[TBL] [Abstract][Full Text] [Related]
28. Validation of usefulness of tissue microarray technology in primary tumours of the canine and feline central nervous system.
Wohlsein P; Recker T; Rohn K; Baumgärtner W
J Comp Pathol; 2012 May; 146(4):320-6. PubMed ID: 22000078
[TBL] [Abstract][Full Text] [Related]
29. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.
Di Palma S; Collins N; Bilous M; Sapino A; Mottolese M; Kapranos N; Schmitt F; Isola J
J Clin Pathol; 2008 Jun; 61(6):757-60. PubMed ID: 18326010
[TBL] [Abstract][Full Text] [Related]
30. BP1, a putative signature marker for inflammatory breast cancer and tumor aggressiveness.
Man YG; Schwartz A; Levine PH; Teal C; Berg PE
Cancer Biomark; 2009; 5(1):9-17. PubMed ID: 19242057
[TBL] [Abstract][Full Text] [Related]
31. Concordance between tissue microarray and whole-section estrogen receptor expression and intratumoral heterogeneity.
Gulbahce HE; Gamez R; Dvorak L; Forster C; Varghese L
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):340-3. PubMed ID: 22495371
[TBL] [Abstract][Full Text] [Related]
32. A new approach to the validation of tissue microarrays.
Goethals L; Perneel C; Debucquoy A; De Schutter H; Borghys D; Ectors N; Geboes K; McBride WH; Haustermans KM
J Pathol; 2006 Apr; 208(5):607-14. PubMed ID: 16435284
[TBL] [Abstract][Full Text] [Related]
33. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers.
Camp RL; Neumeister V; Rimm DL
J Clin Oncol; 2008 Dec; 26(34):5630-7. PubMed ID: 18936473
[TBL] [Abstract][Full Text] [Related]
34. Comparative evaluation of high-throughput small-core (0.6-mm) and large-core (2-mm) thyroid tissue microarray: is larger better?
Jones S; Prasad ML
Arch Pathol Lab Med; 2012 Feb; 136(2):199-203. PubMed ID: 22288969
[TBL] [Abstract][Full Text] [Related]
35. Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure.
Sapino A; Marchiò C; Senetta R; Castellano I; Macrì L; Cassoni P; Ghisolfi G; Cerrato M; D'Ambrosio E; Bussolati G
Virchows Arch; 2006 Sep; 449(3):288-96. PubMed ID: 16770642
[TBL] [Abstract][Full Text] [Related]
36. Standardized on-slide control for quality assurance in the immunohistochemical assessment of therapeutic target molecules in breast cancer.
Mengel M; Hebel K; Kreipe H; von Wasielewski R
Breast J; 2005; 11(1):34-40. PubMed ID: 15647076
[TBL] [Abstract][Full Text] [Related]
37. HER-2/neu analysis in breast cancer bone metastases.
Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
[TBL] [Abstract][Full Text] [Related]
38. A simple and economical method for the manual construction of well-aligned tissue arrays.
Wang SL; Yang CH; Chen HH; Chai CY
Pathol Res Pract; 2006; 202(6):485-6. PubMed ID: 16563652
[TBL] [Abstract][Full Text] [Related]
39. Inter- and intra-observational variability in immunohistochemistry: a multicentre analysis of diffuse large B-cell lymphoma staining.
Lawrie CH; Ballabio E; Soilleux E; Sington J; Hatton CS; Dirnhofer S; Tzankov A
Histopathology; 2012 Jul; 61(1):18-25. PubMed ID: 22372580
[TBL] [Abstract][Full Text] [Related]
40. Tape transfer sectioning of tissue microarrays introduces nonspecific immunohistochemical staining artifacts.
Catchpoole D; Mackie N; McIver S; Chetcuti A; Henwood A; Graf N; Arbuckle S
Biotech Histochem; 2011 Dec; 86(6):421-8. PubMed ID: 21091080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
